Physicians' Academy for Cardiovascular Education

PCSK9

Recently added learning

Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Diverse study data confirm the rationale of intensive lipid-lowering

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

3' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Role of PCSK9 in the regulation of LDL cholesterol

Sep. 12, 2016

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Steps forward in lipid-lowering therapy

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
##FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##FULL_TITLE##

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##FULL_TITLE##

IMPROVE-IT: Implications for clinical practice & guidelines

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof. Kausik Ray
##FULL_TITLE##

Confirmation LDL-c lowering beyond current borders with non statin therapy is effective

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof Erik Stroes
##FULL_TITLE##

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##FULL_TITLE##

Critique on the new AHA / ACC guidelines for lipid management

10' education - Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##FULL_TITLE##

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

3' education - Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD
##FULL_TITLE##

IMPROVE-IT: Scenarios for understanding the results

3' education - Sep. 9, 2014 - Barcelona - Prof Chris Packard
##FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

PCSK9: The promise of a new target in lipid management

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014
##FULL_TITLE##

LDL Receptor Function and Life Cycle

3' education - Dec. 27, 2013
##FULL_TITLE##

Targeting fasting and post-prandial triglycerides

3' education - Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan

PCSK9: the new lipid target in preventive cardiology?

10' education - Sep. 26, 2013
##FULL_TITLE##

The roadmap of PCSK9 inhibitors towards the clinic

10' education - Sep. 30, 2013
##FULL_TITLE##

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

10' education - Sep. 30, 2013
##FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

10' education - Sep. 30, 2013
##FULL_TITLE##

Lowering of LDL-C: Novel concepts and novel promises

10' education - Sep. 14, 2013
##FULL_TITLE##

PCSK9 & LDL- The best story of translational medicine?

3' education - Sep. 8, 2013 - Amsterdam, August 31, 2013 - Dr Evan Stein
##FULL_TITLE##

Treating the untreatable high LDL-c

3' education - June 17, 2013 - Kuala Lumpur - Dato' dr Khoo Kah Lin
##FULL_TITLE##

Antibodies against PCSK9: A new LDL-c lowering therapy?

3' education - Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam

On demand 10" video

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##FULL_TITLE##

Critique on the new AHA / ACC guidelines for lipid management

10' education - Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

PCSK9: The promise of a new target in lipid management

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014

PCSK9: the new lipid target in preventive cardiology?

10' education - Sep. 26, 2013
##FULL_TITLE##

The roadmap of PCSK9 inhibitors towards the clinic

10' education - Sep. 30, 2013
##FULL_TITLE##

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

10' education - Sep. 30, 2013
##FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

10' education - Sep. 30, 2013
##FULL_TITLE##

Lowering of LDL-C: Novel concepts and novel promises

10' education - Sep. 14, 2013

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD
Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and Kastelein talk about this topic in depth and exchange views.

Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD
Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies via PCSK9 inhibition, that was held during the virtual ESC 2020 congress.

Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies with a specifiek focus on PSCK9 inhibition that was held during the virtual ESC 2020 congress.

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME
Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.

Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9i and CV risk.

Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for HeFH, inclisiran (a small interfering RNA against PCKS9) was equally effective in reducing LDL-c.

EAS 2020 A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for heterozygous FH, inclisiran was equally effective in reducing LDL-c.

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME
Prof. Stroes discusses the efficacy of PCSK9 and which patients benefit most from LDL-c lowering (combination) therapies.

Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME
Prof. Mach discusses how CV risk and circulating LDL-c can be reduced by lipid-lowering agents and current guideline recommendations to manage CV risk.

Prof. Mach discusses the concepts for lipid lowering treatment as defined in the 2019 ESC/EAS dyslipidemia guidelines.

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands
Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the role of Lp(a) on CV outcomes.

Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD
At the end of the FOURIER trial studying evolocumab, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD
A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD
Prof. Laufs points out the new emphasis in the ESC/EAS Dyslipidaemia Guidelines on high-risk patients, and shares evidence that forms the rationale for the treatment recommendations.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia
The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD
In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.

In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD
Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.

Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach
Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD
Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Cholesterol guidelines in need of major changes?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

Are very low LDL-c levels safe?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

LDL-c as target in cardiology: The road towards lower targets

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Guidelines and the role of non-statin therapies for high risk ASCVD patients

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME
There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9 inhibitors: How do they work?

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME
Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

AHA 2018 - Chicago, IL, USA

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD
In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

AHA 2018 - Chicago, IL, USA

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA
Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France
In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018
Learn more about the mission of PACE-CME

Learn more about PACE-CME, our mission, our programmes and our cardiovascular educational services and resources

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa
Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA
Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these studies in two different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.

ACC 2018 Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these 2 studies in 2 different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK
Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.

ACC 2018 Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands
Besides the expected effect on prevention of MI, alirocumab was also associated with a decrease of total mortality. In addition, the results give insight in the group of patients that will benefit the most from this drug.

ACC 2018 Besides the expected effect on prevention of MI, alirocumab was also associated with a decrease of total mortality. In addition, the results give insight in the group of patients that will benefit the most from this drug.

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France
Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Prof Kees Hovingh held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

Diverse study data confirm the rationale of intensive lipid-lowering

ESC 2017 - Barcelona

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.

Imaging components of plaque not more informative than burden of plaque

ESC 2017 Barcelona

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when PCSK9 inhibitor evolocumab was added to intensive statin-treatment.

ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

ESC 2017 A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

LDL-c still reduced after 1 year with siRNA against PCSK9

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

ESC 2017 Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works, it is safe, and you cannot force biology

PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA
Prof. Wolfgang Koenig argues that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. He expects that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
Prof. Richard Hobbs states that PCSK9 inhibition reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy and puts the data into perspective of other trials and molecules.

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Prof. John Kastelein argues that after FOURIER and SPIRE 1&2, there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017
Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patient, as a consequence of development of antibodies against the drug.

ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
Implementation of PCSK9 inhibition in clinical practice before the outcome data

CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

AHA 2016 Prof. John JP Kastelein, MD summarises the promising results of the pivotal GLAGOV and ORION-1 trials, presented at the AHA 2016. In GLAGOV, atheroma regression was seen with evolocumab treatment, and in ORION-1 RNA-interference directed against PCSK9 yielded durable LDL-c lowering effect.

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
Epigenetic apabetalone or RVX-208 that alters chromatin structure and gene activity gave clinical benefit in phase 2 study.

AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##KEY_PHRASE##

AHA 2016 The ORION-1 study evaluated different doses of inclisiran, which prevents hepatic PCSK9 production by RNA interference. With a single injection, about 50% LDL-c reduction was achieved, and maintained through 90 days.

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##KEY_PHRASE##

AHA 2016 Prof. Wouter Jukema summarises new insights presented at the AHA, including failing HDL-modifying therapy in the MILANO-PILOT study, a promising effect of a PCSK9 antibody on top of statin on atheroma volume in GLAGOV, and profound LDL-lowering after blocking PCSK9 synthesis in ORION-1.

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##KEY_PHRASE##

AHA 2016 Dr. Steve Nissen shares the results of the GLAGOV study, in which evolocumab added to a statin yielded more regression of atheroma volume than statin therapy alone, with an even stronger response in patients with relatively low LDL-c levels.

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##KEY_PHRASE##

Patrick Moriarty shares the results of the ODYSSEY-ESCAPE trial, set up to evaluate whether treatment with alirocumab could diminish or eradicate the need for lipoprotein apheresis FH patients with severely elevated LDL-c.

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Erik Stroes, MD, explains why further LDL-C lowering therapies are needed and what is the potential role of PCSK9-inhibitors in ACS patients.

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Paul Ridker explains why additional agents beyond statins are needed and describes the development of PCSK9 inhibitors

This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Gilles Lambert, MD describes the discovery and biology of PCSK9 and the effect of PCSK9-inhibitors on LDL-C and Lp(a).

Role of PCSK9 in the regulation of LDL cholesterol

A Mechanism of Action impression

Sep. 12, 2016
A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol

A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016
A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
Lp(a) levels are hardly responsive to currently available drugs, but novel therapeutic options are in development to lower this CV risk factor.

Individuals with elevated Lp(a) levels are at increased CV risk. Lp(a) levels are hardly responsive to currently available medication, so new therapeutic strategies are needed. Prof. Stroes summarises our understanding of Lp(a)-induced atherogenesis and how this may be targeted with novel therapies.

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

John Kastelein, MD (Amsterdam, The Netherlands) indicates the position of PCSK9-inhibitors in current lipid management, especially in patients with FH.

Steps forward in lipid-lowering therapy

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
Robert Giugliano summarises the recent evidence on lipid-lowering therapies beyond statins, in particular ezetimibe and PCSK9 inhibitors, with which further LDL-lowering can be achieved.

Robert Giugliano summarises the recent evidence on lipid-lowering therapies beyond statins, with which further LDL-lowering can be achieved.

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##KEY_PHRASE##

ACC 2016 Data from the GAUSS-3 study show that muscle-related statin intolerance is a real problem and PCSK9 inhibition with evolocumab dramatically reduces LDL-c in these patients.

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##KEY_PHRASE##

The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##KEY_PHRASE##

Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Paul M Ridker, MD Harvard Medical School, Boston, USA

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##KEY_PHRASE##

Prof Paul Ridker describes the remarkable history of the lipid hypothesis and the potential role of PCSK9 inhibition

Lipid Management 2020: A glance at the future

Kausik Ray, Imperial College London, UK

10' education - Sep. 24, 2015
##KEY_PHRASE##

Prof Kausik Ray provides his view on upcoming changes in lipid management and potential solutions to address new challenges

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Bertrand Cariou presents data of a study that investigated the willingness of patients and physicians to use self-injections (either by prefilled pen or a prefilled syringe) to administer the PCSK9-antibody alirocumab.

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Yanan Wang showed in a humanised animal model, the CETP-inhibitor anacetrapib reduced atherosclerosis development, by lowering non-HDL-c levels, via increased uptake in the liver. In addition, anacetrapib reduces plasma PCSK9 levels.

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##KEY_PHRASE##

Lipid MC 2015 Prof. Frederick Raal considers the challenges to adequately lower LDL-c levels in patients with HoFH, and how they may be overcome in the near future.

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##KEY_PHRASE##

Lipid MC 2015 Prof. Kausik Ray provides several reasons why non-HDL-c may be a better lipid parameter than LDL-c to assess risk, to identify high-risk patients and guide treatment.

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##KEY_PHRASE##

Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##KEY_PHRASE##

ACC 2015 Prof. John Kastelein, Amsterdam, comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the potential of PCSK9 inhibitors.

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##KEY_PHRASE##

Prof. John Kastelein, Amsterdam, (PACE director) reviews the major news on the 3 lipoproteins: LDL-c, HDL-c and TG that provide new understanding and implications for the fight against atherosclerosis

IMPROVE-IT: Implications for clinical practice & guidelines

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof. Kausik Ray
##KEY_PHRASE##

Prof. Kausik Ray, London, provides a perspectie on the results of the IMPROVE-IT Trial and its implications for current clinical practice, guidelines and future LDL-c lowering therapies

Confirmation LDL-c lowering beyond current borders with non statin therapy is effective

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof Erik Stroes
##KEY_PHRASE##

Prof. Erik Stroes, Amsterdam talks about a great day for CV medicine and a step forward for future lipid research after the presentation of the IMPROVE-IT trial results

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##KEY_PHRASE##

Dr. Michael J Koren MD, Jacksonville, FL, USA, shares his rationale for targeting PCSK9, based on epidemiology and recent clinical developments and discusses implications for future lipid management 

Critique on the new AHA / ACC guidelines for lipid management

Prof Kausik Ray, Imperial College London, United KIngdom

10' education - Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##KEY_PHRASE##

Lecture by Prof. Kausik Ray, London, United Kingdom, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##KEY_PHRASE##

Dr. Evan Stein, Cincinnati, USA, with an overview of phase III data with the PCSK9 inhibitor evolocumab as were presented in 2014

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##KEY_PHRASE##

Dr. Kees Hovingh, Amsterdam, NL, shares some new insights in the prevalence of Familial Hypercholesterolemia and novel therapeutic options to lower LDL-c in this patient population

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

3' education - Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD
##KEY_PHRASE##

Dr. Paul Ridker, Boston, describes the different inflammatory pathways and ongoing clinical trials targeting inflammation

IMPROVE-IT: Scenarios for understanding the results

3' education - Sep. 9, 2014 - Barcelona - Prof Chris Packard
##KEY_PHRASE##

Prof. Chris Packard (Glasgow) reviews the potential implications of new LDL-c lowering clinical trial outcomes for ezetimibe and new therapeutic options such as PCSK9 inhibitors

HoFH: New insights and expanding therapeutic options

Dr Kees Hovingh, MD, Amsterdam, The Netherlands

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##KEY_PHRASE##

Lecture held by Dr. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands held during the PACE 2014 Snapshot session Novel interventions in cardiovascular disease: Controversies & hot issues in Barcelona.

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##KEY_PHRASE##

Lecture by Prof. Evan Stein, Cincinnati, OH, USA held during EBAC accredited symposium 'Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

Biology and validation of PCSK9 as a novel target to lower LDL-C

Prof. John JP Kastelein

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##KEY_PHRASE##

Lecture by Prof. John Kastelein, Amsterdam, The Netherlands, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

PCSK9: The promise of a new target in lipid management

Prof. John E Deanfield, UCL, London

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##KEY_PHRASE##

Prof. John E Deanfield, London introducing the rationale for PCSK9 inhibition with a lecture held during an EBAC accredited symposium on innovations in lipid management at ESC 2014 in Barcelona

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##KEY_PHRASE##

A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

Emerging therapies to lower LDL-cholesterol

Prof. Erik Stroes, MD

10' education - May 8, 2014
##KEY_PHRASE##

Prof. Erik Stroes describes new treatments to lower LDL-cholesterol: PCSK9-inhibitors, ApoB antisense and MTP-inhibitors, discussing several studies presented recently at the ACC-congress.

LDL Receptor Function and Life Cycle

3' education - Dec. 27, 2013
##KEY_PHRASE##

The first of a new cartoon animated series of mechanisms of action of new developments in atherosclerosis

Targeting fasting and post-prandial triglycerides

3' education - Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan
##KEY_PHRASE##

Dr. Joanne Donovan, describes a potential novel approach to target fasting and post-prandial triglycerides with an oral agent that targets intestinal and liver PCSK9

PCSK9: the new lipid target in preventive cardiology?

ESC Amsterdam, August 31, 2013

10' education - Sep. 26, 2013

The symposium  PCSK9: the new lipid target in preventive cardiology?  ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. Videopresentations from the lectures by John Kastelein, ​Evan Stein, Gilles Lambert and Henry Ginsberg are now available on this website.

The roadmap of PCSK9 inhibitors towards the clinic

Henri Ginsberg, ESC, August 31, 2013

10' education - Sep. 30, 2013
##KEY_PHRASE##

The symposium PCSK9: the new lipid target in preventive cardiology?  ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Henri Ginsberg The roadmap of PCSK9 inhibitors towards the clinic: An overview of current development programs & outcome studies is now available on this website.

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

Gilles Lambert, ESC, August 31, 2013

10' education - Sep. 30, 2013
##KEY_PHRASE##

The symposium PCSK9: the new lipid target in preventive cardiology?  ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Gilles Lambert PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c is now available on this website.

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

Evan Stein, ESC, August 31, 2013

10' education - Sep. 30, 2013
##KEY_PHRASE##

The symposium PCSK9: the new lipid target in preventive cardiology?  ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Evan Stein Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling? is now available on this website.

Lowering of LDL-C: Novel concepts and novel promises

10' education - Sep. 14, 2013
##KEY_PHRASE##

Presentation by prof. Evan Stein during the PACE 2013 SNAPSHOT session on August 31, 2013 in Amsterdam

PCSK9 & LDL- The best story of translational medicine?

3' education - Sep. 8, 2013 - Amsterdam, August 31, 2013 - Dr Evan Stein
##KEY_PHRASE##

Dr Evan Stein with a short overview of current status of development of PCSK9 inhibitors

Treating the untreatable high LDL-c

3' education - June 17, 2013 - Kuala Lumpur - Dato' dr Khoo Kah Lin
##KEY_PHRASE##

Dato' dr Khoo Kah Lin, (Kuala Lumpur, Malaysia) provides his view on current and novel therapeutic options to manage high levels of LDL-c.

Antibodies against PCSK9: A new LDL-c lowering therapy?

3' education - Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam
##KEY_PHRASE##

An introduction by Dr. Kees Hovingh, AMC, Amsterdam on the development of PCSK9-antibodies as a novel strategy to reduce LDL-c.